key: cord-0784161-pahloc0r authors: Jamali, F.; Shahrami, B.; Mojtahedzadeh, A.; Najmeddin, F.; Arabzadeh, A. A.; Hadadi, A.; Sharifzadeh, M.; Mojtahedzadeh, M. title: Changes of LipoxinA4 Levels Following Early Hospital Management of Patients with Non-Severe COVID-19: A Pilot Study date: 2022-04-20 journal: nan DOI: 10.1101/2022.04.18.22273880 sha: cd2afe95920e19aec7e249adde7d2c8af0076787 doc_id: 784161 cord_uid: pahloc0r LipoxinA4 (LXA4) is an anti-inflammatory biomarker participating in the active process of inflammation resolution, which is suggested to be effective on infectious and inflammatory diseases like COVID-19. In this study, we hypothesized that LXA4 levels may increase following COVID-19 treatment and are even more accurate than commonly used inflammatory markers such as erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and ferritin. To test this hypothesis, a pilot study was conducted with 31 adult hospitalized patients with non-severe COVID-19. LXA4 levels were measured at the baseline and 48-72 hours later. Accordingly, ESR and CRP levels were collected on the first day of hospitalization. Moreover, the maximum serum ferritin levels were collected during the five days. LXA4 levels significantly increased at 48-72 hours compared to the baseline. ESR, CRP, and ferritin levels were positively correlated with the increased LXA4. In contrast, aging was shown to negatively correlate with the increased LXA4 levels. LXA4 may be known as a valuable marker to assess the treatment response among non-elderly patients with non-severe COVID-19. Furthermore, LXA4 could be considered as a potential treatment option under inflammatory conditions. Further studies are necessary to clarify LXA4 role in COVID-19 pathogenesis, as well as the balance between such pro-resolving mediators and inflammatory parameters. The current coronavirus belongs to the Coronaviridae family which causes disease in human beings. It firstly emerged in Wuhan, China, but rapidly spread worldwide afterward and extended to a life-threatening pandemic. The virus was named SARS-CoV-2, which causes the coronavirus disease 2019 (COVID-19) [1] . The virus has some spike proteins on its outer surface that are necessary for binding to host cell receptors. When the virus enters the body, the immune system is activated, and the inflammatory processes then begin. Clinical manifestations of viremia can be ranged from asymptomatic to mild, moderate, severe, and critical diseases with exaggerated inflammation and cytokine storm. In severe cases of COVID-19, an uncontrolled inflammatory response with elevated cytokines and chemokines levels can result in multiple organ failures and worse patient's outcomes [2] . Inflammation is an active process associated with the anti-inflammatory mediators' production [3] . These mediators, called specialized pro-resolving mediators (SPMs), are a group of bioactive lipids (BALs) that resulted from arachidonic acid and other polyunsaturated fatty acids metabolisms. Lipoxins (LXs), maresins, protectins, and resolvins are SPMs involved in the active phase of the resolution, which is thought to control inflammation, promote healing, and limit tissue damage. LXs help in the recruitment of neutrophils to the site of inflammation and then in promoting neutrophils' apoptosis to inhibit their excessive accumulation. Accordingly, this biomarker plays a role in the resolution process by delaying the apoptosis of macrophages as well as reducing the secretion of interleukin-8 [4] . It is believed that a complex correlation exists between inflammatory and non-inflammatory mediators in several inflammatory and infectious diseases, including COVID-19 [5] [6] [7] . The data on the role of such mediators in COVID-19 and their exact roles in the treatment and prevention of the disease is still lacking. Up to now, no specific biomarkers have been identified to assess the clinical response in patients with a mild to moderate disease. Moreover, the common biomarkers used to detect the severity of COVID-19 such as erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), and ferritin, are not of high prognostic values [8, 9] . The principal aim of this study was to declare the trend of LXA4 changes in non-severe COVID-19 as well as its correlation with some commonly used inflammatory markers. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (HIS) and patients' records. These patients were followed-up for five days. to 2400 ng/L, and the sensitivity was measured as 9.5 ng/L. Therefore, LXA4 levels below the detection value (<9.5 ng/L) were considered as 9.5 ng/L for the statistical analysis. were collected on the first day of hospital admission and during the hospitalization, respectively. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fifty-six patients were enrolled in the present study, but 25 patients were excluded based on the following exclusion criteria: early death (4 patients), early discharge (16 patients), and receiving investigational drugs (5 patients). Finally, the data obtained from a total of 31 patients were analyzed. A summary of the patients' characteristics and demographics is represented in Table 1 . The mean (±SD) age of the patients, including 18 men and 13 women, was 61.9±17 years old. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Non-steroidal anti-inflammatory drug (NSAID) 0 (0%) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2022. Inflammation is an essential host immune response to pathogens, followed by some active resolution processes to restore homeostasis. LXs are anti-inflammatory mediators that increase at early stages of resolution and promote tissue regeneration, neutrophils apoptosis, macrophage phagocytosis, and cytokine reduction along with other specialized pro-resolving mediators [10] . Despite conducting extensive research on the pro-inflammatory mediators, the pro-resolving roles in COVID-19 have been poorly studied. To the best of our knowledge, this is the first clinical study evaluating serum LX changes among patients with COVID-19. This pilot study showed that LXA4 levels increased in the hospitalized patients with non-severe COVID-19 following performing the early therapeutic interventions. Yang et al. in their study [11] have reviewed the role of SPMs in pulmonary diseases associated with inflammation. They have concluded that LXs and other SPMs have protective effects on the bacterial and viral invasions of the lungs by inhibiting the replication of microorganisms as well as regulating the immune system. Additional studies [12, 13] have shown a significant correlation between severe asthma and the reduced levels of LXA4 in serum and bronchoalveolar All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2022. ; https://doi.org/10.1101/2022.04.18.22273880 doi: medRxiv preprint lavage fluid (BALF). Furthermore, LXs levels significantly decreased in sputum samples of chronic obstructive pulmonary disease (COPD) patients [14] . The imbalance between inflammatory factors results in hypo-differentiation to M2 macrophages, the accumulation of apoptotic cells, and progressive fibrosis in the airways [11] . The role of SPMs in infectious diseases was reviewed in a study by Shayna Sandhaus and Andrew G. Swick [15] . In animal models of sepsis, LXA4, Maresin R1, and resolvins by suppressing the NF-κB pathway effectively reduced systemic inflammation, bacterial burden, and pro-inflammatory mediators' production [16] [17] [18] . SPMs also showed some positive effects on treating sepsis, improving survival, and reducing the need for antibiotics [19] . In the context of the influenza virus, SPMs in preclinical studies were found to be inversely correlated with both the severity and dissemination of more virulent strains [20] . In addition, SPMs like LXB4 showed potential properties in enhancing the immunity of the influenza vaccine by increasing antibody titers through the B cell activation [21] . While previous studies have shown great promise in improving outcomes in the field of infectious and inflammatory diseases, some suggest that the resolution's timing is a paramount factor playing a role in establishing a proper inflammatory response [15] . In a mouse model of pneumosepsis, LXA4 treatment at the early stages of sepsis worsened the outcomes, while at the later stages, it improved survival and inflammation [22] . However, other studies showed the beneficial effects of early administration of SPMs on sepsis [15] . In tuberculosis infection, a sharp increase was observed in proinflammatory and anti-inflammatory mediators in the acute phase of disease in mice, where exogenous SPM could impair the balance between inflammatory properties and the Th1mediated immune response [23] . However, the timely administration of SPMs could reduce TNF-α production and bacterial growth in human macrophages [24] . There are reports of the involvement of lipid mediators in COVID-19, stating that when human cells are exposed to SARS-CoV-2 and the human coronavirus 229E (HCoV-229E), they secrete large amounts of BALs, which then inactivate the virus [25, 26] . Yan B et al. in their study [25] have found that administering linoleic acid and arachidonic acid to Huh-7 cells infected with HCoV-229E and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) could interfere with virus replication. Additionally, Anne-Sophie Archambault et al. [27] have assessed the lipid storm in severe cases of COVID-19 by measuring the BALs concentrations in BALF. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Most SPMs are detectable in the BALF of patients, among which LXA4 is the most significant one. In addition, the levels of SPMs and pro-inflammatory lipids such as prostaglandins (PG) and leukotrienes, were simultaneously high, which indicated the coexistence of such mediators in the acute phase of inflammation, while the resolution process was not fully engaged. LXA4 was indicated to have a significant correlation with PGE2, PGD2, and thromboxane B4, but it had no significant correlation with clinical parameters and aging. In the present study, in contrast, the changes of LXA4 were observed to be correlated with some of the clinical parameters of patients. The increased ESR, CRP, and ferritin were demonstrated to be associated with higher inflammation and more severe disease [28] . The positive correlation of LXA4 with the baseline ESR and CRP levels as well as the maximum ferritin levels in the present study indicated that the patients with higher inflammatory states secreted more LXA4. Correspondingly, this suggests that in a healthy inflammatory process, pro-inflammatory and pro-resolving phases are two sides of the same coin. These results are consistent with previous data presenting that LXA4 elevation occurs due to polyunsaturated fatty acid metabolism in the acute phase of inflammation [27, 29] . As well, it has been suggested that the release of arachidonic acid occurs in two phases in inflammatory events. Firstly, arachidonic acid is metabolized to PGE2 as an inflammatory mediator, anti-inflammatory processes are initiated, and then LXA4 production increases [30] . However, the exact time of this conversion is not fully known yet, and more studies are needed to determine the precise position of LXs in inflammatory processes. Corticosteroids have been shown to suppress the production of LXs along with pro-inflammatory mediators [31, 32] . Corticosteroids appear to be effective in severe cases of COVID-19 in which both excessive inflammatory response and cytokine storm occur [31] . However, early and high doses of corticosteroids in non-severe cases could not be helpful [31] , which may be due to their effect on pro-resolving roles. In this study, another finding was the significant inverse correlation between aging and changes in LXA4 concentration. The effects of aging factors such as immunosenescence and inflammaging on the COVID-19 outcomes have been previously investigated in many studies [33] [34] [35] . The baseline sterile inflammation caused by the increased cytokines produced by senescent cells [36] predisposes the elderly to hyper-inflammatory response and impaired All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. resolution. This hypothesis is consistent with our results, revealing that among elderly patients, the increase in LXA4 was less during early days of the treatment. The present study results suggest that along with the inflammatory response to pathogens, active resolution, and the timely conversion to resolution phase are of great importance in having an effective fight on the coronavirus. Therefore, LXA4 and other SPMs without any immunosuppressive effect may be potential treatment options under inflammatory conditions. Besides, early changes of LXA4 in our study showed that such mediators might be valuable markers for assessing the treatment response compared to common-used inflammatory markers with fewer changes. However, the LXA4 use is not recommended in the elderly population, as the baseline LXA4 levels were below the detection cut-off in many of them and did not significantly increase compared to the non-elderly patients. Although less information is currently available on the possible role of LXA4 following infecting with COVID-19, the present study investigated the trend and pattern of early changes of serum LXA4 among the hospitalized COVID-19 patients. However, this pilot study also had some limitations. Firstly, the small sample size made it difficult to interpret our findings. The second limitation is the lack of a control group. Next, we did not explore the factors affecting LXA4 serum levels, including the onset of symptoms in patients, comorbidities, and medication history. Moreover, we did not exclude the patients receiving anti-inflammatory drugs (e.g., corticosteroids) before the second sampling. LXA4 is suggested to be a beneficial biomarker in infectious and inflammatory diseases like COVID-19. This pilot study showed that LXA4 increased shortly after therapeutic interventions among hospitalized patients with non-severe COVID-19. Moreover, it was significantly correlated with patients' aging and inflammatory markers. Further studies are needed to clarify the role of LXA4 in the pathogenesis of COVID-19 as well as the balance between inflammatory and anti-inflammatory mediators. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 20, 2022. ; https://doi.org/10.1101/2022.04.18.22273880 doi: medRxiv preprint 13 All data generated or analyzed during this study are included in this published article. The authors declare that they have no known competing interests that could have appeared to influence the work reported in this paper. This work was supported by TUMS. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses The trinity of COVID-19: immunity, inflammation and intervention Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms Lipoxins: nature's way to resolve inflammation All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted A Possible Guide as a Tool to Complementary Effects of New Coronavirus The Controversies Surrounding Tocilizumab Administration Following Pathogen-Associated Molecular Pattern (PAMP) Induced by COVID-19 Prognostic biomarkers in COVID-19 infection: value of anemia, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and D-dimer Unexplained elevation of erythrocyte sedimentation rate in a patient recovering from COVID-19: A case report Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm Role of specialized pro-resolving lipid mediators in pulmonary inflammation diseases: mechanisms and development Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma Exhaled breath condensate eicosanoid levels associate with asthma and its severity Lipoxygenase-derived arachidonic acid metabolites in chronic obstructive pulmonary disease All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Lipoxin a4 increases survival by decreasing systemic inflammation and bacterial load in sepsis Maresin 1 mitigates inflammatory response and protects mice from sepsis Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis Combination therapy of 15-Epi-Lipoxin A4 with antibiotics protects mice from Escherichia coli-Induced sepsis Specialized proresolving mediators in innate and adaptive immune responses in airway diseases Lipoxin B4 enhances human memory B cell antibody production via upregulating cyclooxygenase-2 expression Dual role of lipoxin A4 in pneumosepsis pathogenesis Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenasedependent lipoxin production Resolvin D1 (RvD1) and maresin 1 (Mar1) contribute to human macrophage control of M. tuberculosis infection while resolving inflammation All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Bioactive lipids in COVID-19-further evidence Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites Association of inflammatory markers with the severity of COVID-19: a metaanalysis Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Bioactive lipids as mediators of the beneficial action (s) of mesenchymal stem cells in COVID-19 Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019 Research Corticosteroid suppression of lipoxin A Underlying vulnerabilities to the cytokine storm and adverse COVID-19 outcomes in the aging immune system COVID-19 and crosstalk with the hallmarks of aging COVID-19 and the elderly: insights into pathogenesis and clinical decisionmaking All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted The research was previously presented as an abstract at the 6 th international conference on prevention & infection control (ICPIC 2021). All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.